Advertisement

Infection

, Volume 38, Issue 2, pp 131–134 | Cite as

Immune-Mediated Severe Hemolytic Crisis with a Hemoglobin Level of 1.6 g/dl Caused by Anti-Piperacillin Antibodies in a Patient with Cystic Fibrosis

  • S. KunzmannEmail author
  • W. Thomas
  • B. Mayer
  • S. Kuhn
  • H. Hebestreit
Case Report

Abstract

We report a 23-year-old female patient with cystic fibrosis developing severe intravascular hemolysis with a minimal hemoglobin level of 1.6 g/dl after 7 days of treatment with piperacillin, consistent with an immune-mediated hemolytic crisis. Twenty days later, the patient could leave the hospital in good condition without any neurological deficit. To our knowledge, this is the lowest reported hemoglobin value caused by hemolytic anemia with intact survival. As piperacillin is commonly used in patients with cystic fibrosis, it is important to monitor the full-blood counts of patients during treatment with piperacillin and to be aware of the potential for hemolytic anemia to develop. Anti-piperacillin antibodies should be considered whenever these patients develop hemolytic anemia or a positive direct antiglobulin test (DAT). Furthermore, drug-fever under piperacillin application could be a warning sign for the development of hemolytic anemia.

Keywords

Hemolytic Anemia Meropenem Colistin Piperacillin Rasburicase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pleasants RA, Walker TR, Samuelson WM: Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106: 1124–1128.CrossRefPubMedGoogle Scholar
  2. 2.
    Taccetti G, Campana S, Neri AS, Boni V, Festini F: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. J Chemother 2008; 20: 166–169.PubMedGoogle Scholar
  3. 3.
    Macfarlane PI, Hughes DM, Landau LI, Olinsky A: The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study. Pediatr Pulmonol 1985; 1: 249–255.CrossRefPubMedGoogle Scholar
  4. 4.
    Stead RJ, Kennedy HG, Hodson ME, Batten JC: Adverse reactions to piperacillin in adults with cystic fibrosis. Thorax 1985; 40: 184–186.CrossRefPubMedGoogle Scholar
  5. 5.
    Stead RJ, Kennedy HG, Hodson ME, Batten JC: Adverse reactions to piperacillin in cystic fibrosis. Lancet 1984; 1: 857–858.CrossRefPubMedGoogle Scholar
  6. 6.
    Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL: Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101–109.CrossRefPubMedGoogle Scholar
  7. 7.
    McDonnell TJ, FitzGerald MX: Cystic fibrosis and penicillin hypersensitivity. Lancet 1984; 1: 1301–1302.CrossRefPubMedGoogle Scholar
  8. 8.
    Levine B, Redmond A: Immunochemical mechanisms of penicillin induced Coombs positivity and hemolytic anemia in man. Int Arch Allergy Appl Immunol 1967; 31: 594–606.CrossRefPubMedGoogle Scholar
  9. 9.
    Petz LD, Fudenberg HH: Coombs-positive hemolytic anemia caused by penicillin administration. N Engl J Med 1966; 274: 171–178.PubMedCrossRefGoogle Scholar
  10. 10.
    White JM, Brown DL, Hepner GW, Worlledge SM: Penicillin-induced hemolytic anemia. Br Med J 1968; 3: 26–29.CrossRefPubMedGoogle Scholar
  11. 11.
    Salama A, Berghöfer H, Mueller-Eckhardt C: Detection of cell-drug (hapten)-antibody complexes by the gel test. Transfusion 1992; 32: 554–556.CrossRefPubMedGoogle Scholar
  12. 12.
    Arndt PA, Garratty G, Hill J, Kasper M, Chandrasekaran V: Two cases of immune hemolytic anemia, associated with anti-piperacillin, detected by the ‘immune complex’ method. Vox Sang 2002; 83: 273–278.CrossRefPubMedGoogle Scholar
  13. 13.
    Petz LD: Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 1993; 7: 242–254.PubMedGoogle Scholar
  14. 14.
    Petz LD, Mueller-Eckhardt C: Drug-induced immune hemolytic anemia. Transfusion 1992; 32: 202–204.CrossRefPubMedGoogle Scholar
  15. 15.
    Salama A: Drug-induced immune hemolytic anemia. Expert Opin Drug Saf 2009; 8: 73–79.CrossRefPubMedGoogle Scholar
  16. 16.
    Borinstein SC, Xu M, Hawkins DS: Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia. Pediatr Blood Cancer 2008; 50: 189.CrossRefPubMedGoogle Scholar
  17. 17.
    Johnson ST, Weitekamp LA, Sauer DE, Fueger JT, Aster RH: Piperacillin-dependent antibody with relative specificity reacting with drug treated red cells and untreated red cells in the presence of drug. Transfusion 1994; 34: S290.CrossRefGoogle Scholar
  18. 18.
    Thickett KM, Wildman MJ, Fegan CD, Stableforth DE: Haemolytic anemia following treatment with piperacillin in a patient with cystic fibrosis. J Antimicrob Chemother 1999; 43: 435–436.CrossRefPubMedGoogle Scholar
  19. 19.
    Bressler RB, Huston DP: Piperacillin-induced anemia and leukopenia. South Med J 1986; 79: 255–256.PubMedGoogle Scholar
  20. 20.
    Broadberry RE, Farren TW, Bevin SV, Kohler JA, Yates S, Skidmore I, Poole J, Garratty G: Tazobactam-induced hemolytic anemia, possibly caused by non-immunological adsorption of IgG onto patient’s red cells. Transfus Med 2004; 14: 53–57.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia Gala JM, Vazquez Aller S, Rodriguez Vicente P, Morante Pombo C: Immune hemolysis due to piperacillin/tazobactam. Transfus Apher Sci 2009; 40: 97–98.CrossRefPubMedGoogle Scholar
  22. 22.
    Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H: Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003; 98: 1048–1054.CrossRefPubMedGoogle Scholar
  23. 23.
    Browning LA, Kruse JA: Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005; 39: 1932–1935.CrossRefPubMedGoogle Scholar
  24. 24.
    Sanofi-Aventis. Elitek (rasburicase) package insert. Available online at: http://products.sanofi-aventis.us/elitek/elitek.pdf, 2009.

Copyright information

© Urban & Vogel München 2010

Authors and Affiliations

  • S. Kunzmann
    • 1
    Email author
  • W. Thomas
    • 1
  • B. Mayer
    • 2
  • S. Kuhn
    • 3
  • H. Hebestreit
    • 1
  1. 1.University Children’s HospitalUniversity of WürzburgWürzburgGermany
  2. 2.Institute for Transfusion Medicine, Campus Virchow-KlinikumCharité – Universitätsmedizin BerlinBerlinGermany
  3. 3.Institute for Transfusion MedicineUniversity of WürzburgWürzburgGermany

Personalised recommendations